BIO 2024: Impact of Biosecure Act on the Pharma Industry
Pharmaceutical Technology® spoke with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.
As the bio/pharmaceutical industry gets ready for BIO 2024, the PharmTech Group sat down with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, to discuss the impact of the Biosecure Act on the bio/pharmaceutical industry. Shalmou also provided his input on how companies can scale up manufacturing practices and how the use of continuous manufacturing in biopharma is progressing.
“We appreciate that [the Biosecure Act] is an important act designed to protect the health of citizens of this country. And we know we must do everything we can to avoid any unintended, potentially harmful use of our services as highlighted in the act,” says Shamlou. “[We] have put in place a robust contingency plan as well as a CMC [chemistry, manufacturing, and controls] strategy that are designed to mitigate any such risk to supply chain and the development of the assets that our clients bring to us.”
When it comes to continuous manufacturing in biopharmaceutical manufacturing, Shamlou believes the progress made in upstream processing can be made in downstream processing as well. “[In] the next few years, we'll see the introduction of continuous processing into downstream areas. And again, there are technologies out there, but those technologies will grow and will become, I believe, together with additional control strategy, more robust and will be ready for transition into manufacturing.”
View the video above for our full interview with Parviz Shamlou. Abzena is showcasing its services at the BIO 2024 convention in San Diego, Calif., which is being held June 3–6.
